Flavesone

Flavesone and pregnancy

Not Recommended

• Hormone disruptor
• Fetal development

Flavesone is a prenylated flavonoid with documented estrogenic activity, meaning it can interact with estrogen receptors in the body. During pregnancy, hormonal balance is critical for fetal development, and exposure to compounds with estrogenic effects raises theoretical concerns. While specific studies on topical flavesone use during pregnancy are lacking, the general medical consensus is to avoid phytoestrogens and other hormone-disrupting compounds during pregnancy when possible. ACOG recommends caution with any substance that may interfere with the carefully regulated hormonal environment needed for healthy fetal development. The first trimester is particularly sensitive, as hormonal disruption during organogenesis could theoretically affect development. Most obstetricians and dermatologists recommend that pregnant women avoid cosmetic ingredients with known estrogenic activity as a precautionary measure. Given the limited safety data and the presence of safer alternatives, avoiding flavesone during pregnancy is the more conservative approach.

Flavesone and breastfeeding

Caution Advised

• Hormone disruptor
• Infant exposure

Flavesone's estrogenic properties raise concerns during breastfeeding, though the extent of systemic absorption from topical cosmetic use and potential transfer to breast milk is unknown. Phytoestrogens can theoretically affect infant hormonal development if exposure occurs through breast milk. While specific data on flavesone transfer to breast milk is lacking, the AAD generally advises caution with hormone-active compounds during lactation. The potential effects on infant development from hormone-mimicking substances remain a theoretical concern. Many healthcare providers recommend avoiding cosmetic ingredients with estrogenic activity during breastfeeding as a precautionary approach until more safety data becomes available. Safer antioxidant alternatives exist that provide similar benefits without hormonal activity.

Flavesone and postpartum

Safe to Use

For postpartum women not breastfeeding, flavesone's estrogenic activity poses minimal concern. The ingredient's antioxidant and anti-inflammatory properties may be beneficial for skin recovery after pregnancy. While the ingredient has hormonal activity, this is less concerning outside of pregnancy and breastfeeding. Women in this category can use products containing flavesone, though those with hormone-sensitive conditions should exercise caution.

Flavesone and trying to conceive

Caution Advised

• Hormone disruptor
• Fertility effects

Women trying to conceive should consider avoiding ingredients with estrogenic activity like flavesone. While topical absorption from cosmetics is minimal, and no specific fertility concerns have been documented, hormonal balance is important when attempting conception. Most fertility specialists recommend minimizing exposure to hormone-disrupting compounds during the preconception period. Given the availability of safer alternatives with similar benefits, avoiding flavesone is a reasonable precautionary measure.

Flavesone and PCOS

Caution Advised

• Interferes with hormones

Flavesone's estrogenic activity creates uncertainty for women with PCOS, a condition characterized by hormonal imbalance. While some phytoestrogens might theoretically help balance excess androgens, the effects of topical flavesone on systemic hormone levels are unknown and unpredictable. Women with PCOS often take medications to regulate hormones, and introducing ingredients with estrogenic activity could theoretically interfere with treatment, though topical absorption is likely minimal. The lack of specific research on flavesone in PCOS makes it difficult to predict effects. Many endocrinologists recommend that women with PCOS avoid unnecessary exposure to hormone-active compounds until their condition is well-managed. Safer anti-inflammatory ingredients exist without hormonal concerns.

Flavesone and general use

Safe to Use

For the general population without hormone-sensitive conditions or reproductive concerns, flavesone appears to be reasonably safe in cosmetic formulations. The antioxidant and anti-inflammatory properties provide skincare benefits. While the ingredient has estrogenic activity, the systemic absorption from topical cosmetic use is likely minimal. Most healthy adults can use products containing flavesone without significant concern. Individuals with hormone-sensitive conditions (such as hormone-dependent cancers or thyroid disorders) should consult healthcare providers before using products with phytoestrogens. For most people, flavesone is a functional cosmetic ingredient with limited risk.

Everything else flagged for the same profiles

• Flagged in pregnancy
• Flagged in breastfeeding
• Flagged in trying to conceive
• Flagged in PCOS

Related ingredients

Ingredients suggested in place of Flavesone, each one with its own page here.

• Niacinamide
• Resveratrol
• Azelaic Acid

Ingredients that raise the same concerns.

• Butylphenyl MethylpropionalFertility effects, Interferes with hormones, Fetal development
• Benzophenone-3Fertility effects, Interferes with hormones, Fetal development
• IsobutylparabenFertility effects, Interferes with hormones, Fetal development
• 4-Methylbenzylidene CamphorFertility effects, Interferes with hormones, Fetal development
• CannabidiolFertility effects, Interferes with hormones, Fetal development
• Cimicifuga Racemosa Root ExtractFertility effects, Interferes with hormones, Fetal development

Where this came from

Truva summarises published guidance from bodies including ACOG, the FDA, the EU SCCS and the Cosmetic Ingredient Review. It has no access to your medical history and it is not a substitute for your doctor, dermatologist or midwife. These assessments have not been reviewed by a clinician, and nothing here is a diagnosis or a prescription. If you are pregnant, breastfeeding or being treated for PCOS, take the ingredient list to the person looking after you.

Assessment last pulled from the ingredient database on 15 September 2026.